UCSF
The UCSF Center for Maternal-Fetal Precision Medicine is an academic research center developing prenatal genomic diagnostics and in utero molecular therapies (stem cell transplantation, enzyme replacement, gene editing) for high-risk pregnancies and genetic disease, and educating MFM/REI clinicians.
- Company typePrivate
- Founded2015
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
UCSF firmographics
Firmographics- Name
- UCSF
- Legal name
- The Regents of the University of California
- Website
- https://mfprecision.ucsf.edu
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- The UCSF Center for Maternal-Fetal Precision Medicine is an academic research center developing prenatal genomic diagnostics and in utero molecular therapies (stem cell transplantation, enzyme replacement, gene editing) for high-risk pregnancies and genetic disease, and educating MFM/REI clinicians.
- Ownership category
- akta.pro rank
UCSF industry classification
Industry- Product category
- Maternal-Fetal Precision Medicine Research
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Maternal-Fetal Medicine (High-Risk Pregnancy) Centers (HLAFAJAB)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Maternal-Fetal Medicine (High-Risk Pregnancy/Perinatology) (HLAKAJAB), Maternal–Fetal & Neonatal Care Pathways (HLACAGAI)
Keywords
Where UCSF is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
UCSF business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Clinical Research and Clinical Trials: The Center operates as a research entity conducting clinical trials (phase 1 trials for alpha thalassemia major, PEARL trial for lysosomal storage diseases) funded primarily through NIH grants, March of Dimes, California Institute for Regeneration Medicine, and Burroughs-Wellcome Fund. Revenue is not commercial but grant-based.
- Educational Programs: Fellowship programs (Research Fellowship in Fetal Diagnosis and Therapy, Translational Genome Editing & Precision Medicine Fellowship) and Basic Training in Reproductive Medical Genetics courses. Fellowships are fully funded positions; Basic Training courses charge registration fees ($350 per physician in training, $100 for audit/review).
- Donations: The Center accepts donations through the UCSF donation portal to advance research in fetal diagnosis and therapy.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Research Fellowship in Fetal Diagnosis and Therapy - Fully Funded Position |
| Other | Multi-year contract | Translational Genome Editing & Precision Medicine Fellowship - Fully Funded Position |
| Subscription | Annual | Basic Training Part 1 & Part 2 - Physician in Training |
| Subscription | Pay-as-you-go | Basic Training for Practicing Providers - Online Courses |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
UCSF product offering
Product offeringCore offering
The Center for Maternal-Fetal Precision Medicine develops precision diagnostics and in utero molecular therapies for severe fetal genetic diseases. Its core offerings include prenatal exome/genome sequencing, world-first clinical trials of in utero hematopoietic stem cell transplantation for alpha thalassemia major and prenatal enzyme replacement therapy (PEARL Trial) for lysosomal storage diseases, and a translational gene editing pipeline targeting monogenic disorders. It also operates fellowship programs and the Basic Training curriculum for MFM/REI fellows and practicing obstetric providers.
Product overview
The UCSF Center for Maternal-Fetal Precision Medicine is a research and clinical center focused on developing precision diagnostics and fetal molecular therapies for genetic diseases. The portfolio includes Prenatal Exome/Genome Sequencing for genetic diagnosis, clinical trials for in utero therapies (Stem Cell Transplantation, PEARL Trial for enzyme replacement), and educational programs (Translational Genome Editing Fellowship, Basic Training in Reproductive Medical Genetics). Key initiatives include the International Alpha Thalassemia Consortium and patient registries for alpha thalassemia and lysosomal storage diseases.
Differentiator
Problem solved
Functional benefit
Brands
- International Alpha Thalassemia Consortium: An interdisciplinary consortium hosted by the Center that brings together clinicians and scientists from around the world focused on alpha thalassemia major (ATM).
- Basic Training in Reproductive Medical Genetics
- Translational Genome Editing & Precision Medicine Fellowship
- Research Fellowship in Fetal Diagnosis and Therapy
Products and services
- Prenatal Exome/Genome Sequencing Clinical research service using next-generation gene sequencing technology to discover fetal genes that drive abnormalities in utero, including hydrops fetalis, revealing genetic etiologies that elude standard genetic testing. For pregnant women with unexplained fetal ultrasound abnormalities.
- Hydrops Fetalis Research Program Research program developing precision-based approaches to diagnose and care for non-immune hydrops fetalis (NIHF), aiming to improve newborn and maternal outcomes through exome sequencing and novel in utero treatments.
- In Utero Stem Cell Transplantation (Alpha Thalassemia Major Clinical Trial) Phase 1 clinical trial of in utero hematopoietic stem cell transplantation using maternal-derived hematopoietic stem cells to treat fetuses with alpha thalassemia major. The first FDA-approved IND application for in utero stem cell transplantation.
- PEARL Trial (Prenatal Enzyme Replacement for Lysosomal Storage Diseases) Phase 1 clinical trial of enzyme replacement therapy to treat fetuses diagnosed with lysosomal storage diseases (including Pompe disease) before birth to circumvent irreversible organ damage and immune reactions to replacement enzymes. First FDA-approved IND for prenatal enzyme replacement therapy.
- Translational Genome Editing & Precision Medicine Fellowship One- or two-year fully funded research fellowship focused on developing CRISPR-based therapeutic strategies for severe single-gene disorders, integrating human genetics, genome editing, regenerative medicine, and translational therapeutics. Appointed through Department of Surgery at UCSF.
- Research Fellowship in Fetal Diagnosis and Therapy One- or two-year fully funded fellowship supporting research focused on fetal diagnosis and fetal molecular therapies, covering prenatal diagnosis, bioinformatics, and development of new fetal molecular therapies including stem cell or gene therapy. Appointed through UCSF Department of Surgery or Department of Obstetrics, Gynecology & Reproductive Sciences.
- Basic Training in Reproductive Medical Genetics (FoRGE) Comprehensive education curriculum for MFM and REI fellows and practicing obstetric providers in reproductive genetics and genomics, including pre-recorded lectures, live workshops, case presentations, and weekly live rounds. Tracks include Foundations in Genomics and Specialized Clinical Applications in Genomics.
- International Alpha Thalassemia Consortium Global interdisciplinary consortium bringing together clinicians and scientists focused on alpha thalassemia major (ATM), hosting quarterly virtual seminars to share advances, challenges, and best practices in prenatal, pediatric, and adult ATM care. Includes collaborators from Singapore, Netherlands, Toronto, and Arabian Peninsula countries.
- International Registry of Patients with Alpha Thalassemia (ATM Registry) Patient registry collecting prospective and retrospective data on patients diagnosed with alpha thalassemia major and other alpha thalassemia mutations to understand natural history, identify therapy outcomes, and improve clinical management.
- LSD Registry (Lysosomal Storage Diseases Registry) Registry of patients diagnosed with lysosomal storage diseases, supporting research and clinical care for these genetic conditions.
Quantifiable outcome
- First human fetal surgery institution
- +3 more outcomes
Companies that use UCSF
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
UCSF technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
UCSF partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered core, major and minor.
- Department of Obstetrics, Gynecology & Reproductive Sciences (UCSF)coreCore UCSF department partner providing maternal-fetal medicine expertise, clinical faculty, and research infrastructure for prenatal diagnosis and fetal treatment programs.
- Department of Pediatrics (UCSF)coreCore UCSF department partner providing pediatric genetics and clinical trial support for fetal and neonatal conditions.
- Department of Surgery (UCSF)coreCore UCSF department hosting the Center and providing surgical expertise for fetal treatment and pediatric surgery.
- Program in Bioethics (UCSF)coreProvides bioethics expertise and guidance for complex ethical issues in fetal therapy, genetic testing, and emerging technologies.
- Fetal Treatment Center (UCSF)coreSister center providing surgical fetal treatment expertise and clinical infrastructure for fetal interventions.
- Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research (UCSF)coreProvides stem cell research infrastructure, facilities, and collaborative research opportunities for fetal stem cell transplantation studies.
- Innovative Genomics Institute (UC Berkeley)coreCollaboration on genome editing research, CRISPR technologies, and gene therapy development. Center investigators Fyodor Urnov and Petros Giannikopoulos are affiliated with IGI.
- Gladstone InstitutescoreCollaboration on genome editing and cellular biology research. Center investigator Bruce Conklin is affiliated with Gladstone Institutes.
- Institute for Human Genetics (UCSF)coreProvides human genetics expertise, research infrastructure, and faculty collaboration for genomic research programs.
- Columbia University Irving Medical CentermajorLong-standing collaboration on reproductive genetics and prenatal diagnosis. Ronald Wapner serves on the Center Advisory Committee. Multiple collaborative faculty including Paul Appelbaum, Wendy Chung, Jessica Giordano.
- MacKenzie Laboratory (UCSF)coreDr. Tippi MacKenzie's laboratory focusing on stem cell biology and prenatal therapies. Primary research partner for Translational Genome Editing Fellowship.
- Cromer Laboratory (UCSF)coreDr. Kyle Cromer's laboratory focusing on genome editing and gene therapy. Co-leader of Translational Genome Editing Fellowship program.
- Foundation for Reproductive Genetics Education (FoRGE)majorNon-profit foundation founded in 2023 with mission to provide unbiased, comprehensive education on reproductive genetics to healthcare providers. Co-developer of Basic Training curriculum.
- NateraminorProvided unrestricted educational grant for Basic Training in Reproductive Medical Genetics program. Company specializing in non-invasive prenatal testing (NIPT) and expanded carrier screening.
- IlluminaminorProvided unrestricted educational grant for Basic Training program. Leading sequencing technology provider supporting genomic research.
- Billion to OneminorProvided unrestricted educational grant for Basic Training program. Company developing advanced prenatal genetic testing technologies.
- Stanford UniversitymajorCenter investigator Agnieszka Czechowicz from Stanford University. Collaboration on stem cell biology and transplantation research.
- UCLAmajorCenter collaborator Donald Kohn from UCLA specializing in gene therapy and hematology. Contributed to lentiviral gene therapy research for alpha thalassemia.
- University of OxfordmajorCenter collaborator Stephan Sanders from University of Oxford providing bioinformatics and pediatric neurogenetics expertise.
- International Alpha Thalassemia ConsortiumcoreHosted by the Center, this consortium brings together interdisciplinary clinicians and scientists from around the world focusing on alpha thalassemia major. Quarterly virtual seminars share advances, challenges, and best practices in prenatal, pediatric, and adult ATM care.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
UCSF competitors and assessment
Company assessmentDirect peers
- Stanford Medicine Maternal-Fetal Medicine: Geographic peer in the Bay Area with strong maternal-fetal medicine and prenatal genetics programs. Stanford investigators (e.g., Czechowicz) already collaborate with the Center, reflecting overlap in stem-cell-based fetal therapy research.
- Children's Hospital of Philadelphia (CHOP) — Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment: Long-established pioneering fetal therapy center; developed the EXIT procedure and built foundational protocols for open fetal surgery that UCSF's Center parallels. Operates in the same clinical-research niche of in-utero intervention for genetic and anatomic disease with multidisciplinary surgical-genetics teams.
- Johns Hopkins Center for Fetal Therapy: Hopkins-based fetal therapy program with overlapping scope in in-utero interventions and prenatal genetic diagnosis. Competes for national referral volume in fetal surgery and serves as a parallel academic-research-clinical operation.
- UPMC Magee-Womens Research Institute: Major academic maternal-fetal medicine research institute running innovative fetal intervention programs and prenatal diagnosis research. Comparable in operating model: grant-funded academic research combined with clinical trial execution and physician training in reproductive genetics.
- Texas Children's Hospital Fetal Center (Baylor): High-volume fetal intervention center performing open and minimally invasive fetal surgery for genetic and structural anomalies. Comparable mix of clinical trials, prenatal diagnosis, and multidisciplinary fetal-maternal care.
- Cleveland Clinic Fetal Care Center: Multidisciplinary fetal care center offering advanced prenatal diagnosis and in-utero therapies for genetic and structural conditions. Directly competes for complex maternal-fetal referrals and operates a similar academic-research-clinical trial model.
Emerging players
- Billion to One: High-growth prenatal genetic testing company (UNITY screen, etc.) and unrestricted educational grant sponsor of the Center's Basic Training program. Emerging competitor in advanced NIPT and carrier screening, intersecting with the Center's diagnostic and educational channels.
- CRISPR Therapeutics: Clinical-stage CRISPR-based gene editing company (with Vertex via Casgevy) developing in vivo gene-editing therapies. Operates in the same therapeutic modality space — fetal gene editing and rare monogenic disease correction — where the Center runs its Translational Genome Editing pipeline.
Broad incumbents
- Myriad Genetics: Established clinical genetic testing company covering prenatal and hereditary disease screening. Comparable in delivering prenatal diagnostic services to obstetric providers and competing for the same clinical adoption channels the Center trains.
- Natera: Leading commercial provider of NIPT, expanded carrier screening, and prenatal genetic testing; also an unrestricted educational grant sponsor of the Center's Basic Training program. Overlaps in prenatal genomics market and is a potential downstream commercialization or partnership counterparty.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
UCSF social profiles
Digital presenceUCSF financial estimates
Financial estimateRevenue estimate
Valuation estimate
UCSF leadership team
Management profileNumber of profiles
Profiles6 records
UCSF funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UCSF M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UCSF
What does UCSF do?
The Center for Maternal-Fetal Precision Medicine develops precision diagnostics and in utero molecular therapies for severe fetal genetic diseases. Its core offerings include prenatal exome/genome sequencing, world-first clinical trials of in utero hematopoietic stem cell transplantation for alpha thalassemia major and prenatal enzyme replacement therapy (PEARL Trial) for lysosomal storage diseases, and a translational gene editing pipeline targeting monogenic disorders. It also operates fellowship programs and the Basic Training curriculum for MFM/REI fellows and practicing obstetric providers.
Is UCSF a public or private company?
UCSF is a private company. It is classified as state government owned and is currently operating.
When was UCSF founded?
UCSF was founded in 2015. It employs 1 to 10 people.
Where is UCSF based?
UCSF is headquartered in San Francisco, United States, in the North America region.
How does UCSF make money?
Three revenue lines are on record. Clinical Research and Clinical Trials are the primary driver. The others are educational Programs and donations.
Who are UCSF's main competitors?
Direct peers on record are Stanford Medicine Maternal-Fetal Medicine, Children's Hospital of Philadelphia (CHOP) — Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment, Johns Hopkins Center for Fetal Therapy, UPMC Magee-Womens Research Institute, Texas Children's Hospital Fetal Center (Baylor) and Cleveland Clinic Fetal Care Center. Emerging players are Billion to One and CRISPR Therapeutics. Broad incumbents are Myriad Genetics and Natera.
Does UCSF have an API?
No public API is recorded for UCSF.
What industry is UCSF in?
UCSF's product category is Maternal-Fetal Precision Medicine Research. Its primary akta.pro industry code is HLAFAJAB, Maternal-Fetal Medicine (High-Risk Pregnancy) Centers, with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.